9688 Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9688 from our risk checks.
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.76 |
| 52 Week High | US$25.80 |
| 52 Week Low | US$10.56 |
| Beta | 1.04 |
| 11 Month Change | -13.52% |
| 3 Month Change | 42.57% |
| 1 Year Change | -9.57% |
| 33 Year Change | -66.65% |
| 5 Year Change | n/a |
| Change since IPO | -67.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9688 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -8.1% | 2.2% | 1.6% |
| 1Y | -9.6% | -13.1% | 10.1% |
Return vs Industry: 9688 exceeded the Hong Kong Biotechs industry which returned -13.1% over the past year.
Return vs Market: 9688 underperformed the Hong Kong Market which returned 10.1% over the past year.
Price Volatility
| 9688 volatility | |
|---|---|
| 9688 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 9688 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9688's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| 9688 fundamental statistics | |
|---|---|
| Market cap | HK$19.69b |
| Earnings (TTM) | -HK$2.11b |
| Revenue (TTM) | HK$2.77b |
7.1x
P/S Ratio-9.3x
P/E RatioIs 9688 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9688 income statement (TTM) | |
|---|---|
| Revenue | US$355.75m |
| Cost of Revenue | US$395.21m |
| Gross Profit | -US$39.46m |
| Other Expenses | US$231.39m |
| Earnings | -US$270.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | -11.09% |
| Net Profit Margin | -76.13% |
| Debt/Equity Ratio | 16.9% |
How did 9688 perform over the long term?
See historical performance and comparison